Pàgina inicial > Articles > Resultats de la cerca: Treatment

Articles

  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Articles 400 registres trobats  inicianterior66 - 75següentfinal  anar al registre: La cerca s'ha fet en 0.01 segons. 
66.
12 p, 342.1 KB The Role of food addiction and lifetime substance use on eating disorder treatment outcomes / Miranda-Olivos, Romina (Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición) ; Agüera, Zaida (Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición) ; Granero, Roser (Universitat Autònoma de Barcelona. Departament de Psicobiologia i de Metodologia de Ciències de la Salut) ; Jiménez-Murcia, Susana (Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición) ; Puig-Llobet, Montserrat (Universitat de Barcelona. Departament d'Infermeria de Salut Pública, Salut Mental i Maternoinfantil) ; Lluch-Canut, Maria Teresa (Universitat de Barcelona. Departament d'Infermeria de Salut Pública, Salut Mental i Maternoinfantil) ; Gearhardt, Ashley N. (University of Michigan. Department of Psychology) ; Fernández-Aranda, Fernando (Universitat Autònoma de Barcelona. Departament de Psicobiologia i de Metodologia de Ciències de la Salut)
Food addiction (FA) and substance use (SU) in eating disorders (ED) have been associated with a more dysfunctional clinical and psychopathological profile. However, their impact on treatment outcomes has been poorly explored. [...]
2023 - 10.3390/nu15132919
Nutrients, Vol. 15 Núm. 13 (2023) , article 2919  
Registre complet - Creative Commons
67.
10 p, 1.1 MB The Multiple Sclerosis Care Unit / Sørensen, Per S (Copenhagen University Hospital) ; Giovannoni, Gavin (Queen Mary University of London) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Thalheim, Christoph (European Multiple Sclerosis Platform, Brussels) ; Zaratin, Paola (Multiple Sclerosis International Federation (MSIF)) ; Comi, Giancarlo (San Raffaele Hospital, Milan) ; Universitat Autònoma de Barcelona. Departament de Medicina
Treatment of multiple sclerosis (MS) has become increasingly multifaceted and comprises not only a variety of disease-modifying drugs with different mechanism of action but also a wide range of symptomatic therapies. [...]
2019 - 10.1177/1352458518807082
Multiple sclerosis, Vol. 25 Núm. 5 (april 2019) , p. 627-636  
Registre complet - Creative Commons
68.
11 p, 473.7 KB Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting : PROTEC / Berger, Thomas (Universitätsklinik für Neurologie) ; Brochet, B. (Groupe Hospitalier Pellegrin Hôpital Pellegrin) ; Brambilla, L. (IRCCS Foundation Neurological Institute Carlo Besta) ; Giacomini, P.S. (Montreal Neurological Institute Hospital) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Vasco Salgado, A (Hospital Professor Doutor Fernando Fonseca) ; Su, R (Biogen, USA) ; Bretagne, A (Biogen International GmbH) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing-remitting multiple sclerosis (RRMS) disease. Objective: The aim is to evaluate the effectiveness of delayed-release dimethyl fumarate (DMF) on disease activity and PROs in patients with RRMS in the clinic. [...]
2019 - 10.1177/2055217319887191
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 5 Núm. 4 (2019)  
Registre complet - Creative Commons
69.
17 p, 300.8 KB Expert opinion on the use of cladribine tablets in clinical practice / Sørensen, Per Soelberg (University of Copenhagen) ; Centonze, Diego (Unit of Neurology and Neurorehabilitation) ; Giovannoni, Gavin (Queen Mary University of London) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Selchen, Daniel (St. Michael's Hospital, Toronto) ; Vermersch, Patrick (Univ. Lille) ; Wiendl, Heinz (University of Münster) ; Yamout, Bassem (American University of Beirut) ; Salloukh, Hashem (Ares Trading S.A. Merck Serono S.A) ; Rieckmann, Peter (University of Erlangen) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians' questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) unanswered. [...]
2020 - 10.1177/1756286420935019
Therapeutic Advances in Neurological Disorders, Vol. 13 (2020)  
Registre complet - Creative Commons
70.
Biological treatment and microbial composition of landfill leachate using a compost process in an airlift bioreactor / Hernandez del Amo, Elena (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Poblete, Rodrigo (Universidad Católica del Norte. Escuela de Prevención de Riesgos y Medioambiente (Chile)) ; Sánchez Martínez, M. Olga (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Maldonado, Manuel Ignacio (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. Plataforma Solar de Almería)
Landfill leachate (LL) contains a large amount of toxic compounds and its treatment is currently a matter of concern. In this work, an adapted compost in different airlift bioreactors was used to depurate a complex, toxic and old landfill leachate without treatment (raw leachate) and after pretreatments (coagulation/flocculation; coagulation/flocculation and filtration; coagulation/flocculation, filtration and photo-Fenton process). [...]
2023 - 10.1016/j.jclepro.2023.137748
Journal of cleaner production, Vol. 415 (August 2023) , art. 137748  
Registre complet - Creative Commons
71.
14 p, 762.0 KB Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis : Results from ASCLEPIOS I and II / Gärtner, Jutta (University Medical Centre Göttingen) ; Hauser, Stephen L. (University of California, San Francisco) ; Bar-Or, Amit (University of Pennsylvania) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cohen, Jeffrey A. (Cleveland Clinic Foundation) ; Cross, Anne H. (Washington University School of Medicine) ; Deiva, Kumaran (University Hospitals Paris Saclay) ; Ganjgahi, Habib (University of Oxford) ; Häring, Dieter A. (Novartis) ; Li, Bingbing (Novartis) ; Pingili, Ratnakar (Novartis) ; Ramanathan, Krishnan (Novartis) ; Su, Wendy (Novartis) ; Willi, Roman (Novartis) ; Kieseier, Bernd (Novartis) ; Kappos, Ludwig (University of Basel) ; Universitat Autònoma de Barcelona
Background: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide. [...]
2022 - 10.1177/13524585221078825
Multiple sclerosis, Vol. 28 Núm. 10 (2022) , p. 1562-1575  
Registre complet - Creative Commons
72.
8 p, 1.1 MB Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis : Benefit/risk following review of trial and post-marketing data / Coles, Alasdair J. (University of Cambridge) ; Jones, Joanne L. (University of Cambridge) ; Vermersch, Patrick (Université de Lille) ; Traboulsee, Anthony (University of British Columbia) ; Bass, Ann D. (Neurology Center of San Antonio) ; Boster, Aaron (Boster Center for Multiple Sclerosis) ; Chan, Andrew (University of Bern) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Fernández, Óscar (Hospital Regional Universitario Carlos Haya (Málaga)) ; Giovannoni, Gavin (Queen Mary University of London) ; Kubala Havrdova, Eva (Charles University) ; LaGanke, Christopher (North Central Neurology Associates) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Oreja-Guevara, Celia (Universidad Complutense de Madrid) ; Piehl, Fredrik (Karolinska Institutet (Estocolm, Suècia)) ; Wiendl, Heinz (University of Münster) ; Ziemssen, Tjalf (Dresden University of Technology) ; Universitat Autònoma de Barcelona
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35. [...]
2022 - 10.1177/13524585211061335
Multiple sclerosis, Vol. 28 Núm. 5 (2022) , p. 842-846  
Registre complet - Creative Commons
73.
6 p, 852.9 KB Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis / Brochet, Bruno (University of Bordeaux) ; Hupperts, Raymond (Maastricht University Medical Center) ; Langdon, Dawn (Royal Holloway University of London) ; Solari, Alessandra (Fondazione IRCCS Istituto Neurologico Carlo Besta) ; Piehl, Fredrik (Karolinska Institutet (Estocolm, Suècia)) ; Lechner-Scott, Jeannette (Newcastle University. John Hunter Hospital) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Selmaj, Krzysztof (Center for Neurology, Lodz, Poland) ; Valis, Martin (Charles University and University Hospital, Czech Republic) ; Rejdak, Konrad (Medical University of Lublin) ; Havrdova, Eva K. (Charles University, Prague, Czech Republic) ; Patti, Francesco (University of Catania) ; Alexandri, Nektaria (Merck Healthcare KGaA, Darmstadt, Germany) ; Nolting, Axel (Merck Healthcare KGaA, Darmstadt, Germany) ; Keller, Birgit (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. [...]
2022 - 10.1016/j.msard.2021.103385
Multiple Sclerosis and Related Disorders, Vol. 57 (2022) , p. 103385  
Registre complet - Creative Commons
74.
8 p, 696.4 KB Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD : Results from the VERNE study / Bastida Paz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ; Marín-Jiménez, Ignacio (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ; Forés, Ana (Consorci Hospitalari Provincial de Castelló) ; García-Planella, Esther (Institut d'Investigació Biomèdica Sant Pau) ; Argüelles-Arias, Federico (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Tagarro, Ignacio (Takeda Farmacéutica España S.A.) ; Fernandez-Nistal, Alonso (Takeda Farmacéutica España S.A.) ; Montoto, Carmen (Takeda Farmacéutica España S.A.) ; Aparicio, Jesús (Takeda Farmacéutica España S.A.) ; Aguas, Mariam (Hospital Universitari i Politècnic La Fe (València)) ; Santos-Fernandez, Javier (Hospital Universitario Río Hortega (Valladolid)) ; Bosca-Watts, Marta Maia (IBD Unit. Hospital Universitario de Valencia) ; Ferreiro-Iglesias, Rocío (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; Merino, Olga (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Aldeguer, Xavier (Hospital Universitari de Girona Doctor Josep Trueta) ; Cortés Rizo, Xavier (Universidad CEU Cardenal Herrera) ; Sicilia Aladrén, Beatriz (Hospital Universitario de Burgos) ; Mesonero, Francisco (Hospital Universitario Ramón y Cajal (Madrid)) ; Barreiro de-Acosta, Manuel (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Background: Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. [...]
2022 - 10.1016/j.dld.2021.06.005
Digestive and Liver Disease, Vol. 54 Núm. 1 (january 2022) , p. 76-83  
Registre complet - Creative Commons
75.
27 p, 1.3 MB Documento de consenso de asma grave en adultos. Actualización 2022 / Alvarez Gutiérrez, Francisco Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Blanco-Aparicio, Marina (Complejo Hospitalario Universitario de A Coruña) ; Casas-Maldonado, Francisco (Hospital Universitario San Cecilio (Granada)) ; Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau) ; González-Barcala, Francisco Javier (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; Carretero-García, José Ángel (Servicio de Neumología. Hospital Royo Villanova) ; Castilla-Martínez, Manuel (Servicio de Neumología. Hospital Universitario Los Arcos del Mar Menor) ; Cisneros, Carolina (Servicio de Neumología. Hospital Universitario La Princesa. FIB La Princesa) ; Diaz-Pérez, David (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ; Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Martínez-Moragon, Eva (Servicio de Neumología. Hospital Universitario Dr Peset) ; Muñoz Gall, Xavier (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Padilla, Alicia (Unidad de Asma. Hospital Costa del Sol) ; Perpiñá-Tordera, Miguel (Hospital Universitari i Politècnic La Fe (València)) ; Soto-Campos, Gregorio (Unidad de Gestión Clínica de Neumología y Alergia. Hospital Universitario de Jerez)
El asma grave constituye un síndrome heterogéneo con diversas variantes clínicas, y representa en muchas ocasiones una enfermedad compleja con necesidad de un abordaje especializado y multidisciplinar, así como la utilización de múltiples fármacos. [...]
Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. [...]
2022 - 10.1016/j.opresp.2022.100192
Open Respiratory Archives, Vol. 4 (2022) , p. 100192  
Registre complet - Creative Commons

Articles : 400 registres trobats   inicianterior66 - 75següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem